Literature DB >> 21375607

Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.

S K Kumar1, N Gupta, A Rajwanshi, K Joshi, G Singh.   

Abstract

OBJECTIVE: Steroid receptors and human epidermal growth receptor 2 (HER2) have been used for predicting response to treatment in breast cancers. Fine needle aspiration cytology can provide highly cellular material and can be used for such analysis. The present study was undertaken to assess the reliability of oestrogen and progesterone receptor (ER, PR) status and HER2 as demonstrated by immunochemistry (IHC) on cell blocks from breast carcinoma cases, in comparison with histological sections.
METHODS: IHC for ER, PR and HER2 was performed on cell blocks and their corresponding tissue sections of 50 primary pre-chemotherapy breast carcinomas. Positivity for ER and PR was scored according to the Allred scoring system. Strong membranous positivity in more than 30% of tumour cells was considered positive for HER2. The tumours were classified as luminal A, luminal B, HER2-over-expressing and triple negative on the basis of ER, PR and HER2 status and results on cell blocks compared with histological sections.
RESULTS: Correlation between immunostaining on cell blocks and the corresponding tumour tissues revealed a concordance rate for ER, PR and HER2 of 90% [Correlation coefficient (r) = 0.79], 94% (r = 0.86) and 90% (r = 0.76), respectively. Including five cases in which cell blocks were either ER or PR positive, 43/50 cases (86.0%) could be correctly classified on cell block immunostaining alone. The main reasons for seven discordant cases included technical errors (sampling error and staining error) and interpretational error in HER2 evaluation on cell blocks; the core biopsy was inadequate in one, and apparently false negative for HER2 in another.
CONCLUSION: Cell blocks are useful in the assessment of hormone receptor status and HER2 by IHC, especially in cases of locally advanced breast cancer for planning neoadjuvant chemotherapy. It is highly recommended to have good quality cell blocks and quality control of their interpretation.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21375607     DOI: 10.1111/j.1365-2303.2011.00853.x

Source DB:  PubMed          Journal:  Cytopathology        ISSN: 0956-5507            Impact factor:   2.073


  8 in total

1.  Alterations in three biomarkers (estrogen receptor, progesterone receptor and human epidermal growth factor 2) and the Ki67 index between primary and metastatic breast cancer lesions.

Authors:  Kimihito Fujii; Rie Watanabe; Takahito Ando; Junko Kousaka; Yukako Mouri; Miwa Yoshida; Tsuneo Imai; Shogo Nakano; Takashi Fukutomi
Journal:  Biomed Rep       Date:  2017-10-19

Review 2.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Authors:  Angela N Bartley; Mary Kay Washington; Christina B Ventura; Nofisat Ismaila; Carol Colasacco; Al B Benson; Alfredo Carrato; Margaret L Gulley; Dhanpat Jain; Sanjay Kakar; Helen J Mackay; Catherine Streutker; Laura Tang; Megan Troxell; Jaffer A Ajani
Journal:  Am J Clin Pathol       Date:  2016-11-14       Impact factor: 2.493

3.  Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study.

Authors:  Rieko Nishimura; Yuya Murata; Kiyoshi Mori; Katsushige Yamashiro; Kazuya Kuraoka; Shu Ichihara; Kenichi Taguchi; Hiroyoshi Suzuki; Masahiro Ito; Natsumi Yamashita
Journal:  Acta Cytol       Date:  2018-05-15       Impact factor: 2.319

4.  Evaluating Estrogen Receptor Immunohistochemistry on Cell Blocks From Breast Cancer Patients in a Low-Resource Setting.

Authors:  Asteria H Kimambo; Edda A Vuhahula; Amos R Mwakigonja; Britt-Marie Ljung; Li Zhang; Katherine Van Loon; Dianna L Ng
Journal:  Arch Pathol Lab Med       Date:  2021-07-01       Impact factor: 5.686

5.  HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka
Journal:  Diagn Cytopathol       Date:  2016-01-22       Impact factor: 1.582

6.  Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka; Natsumi Yamashita
Journal:  Breast Cancer       Date:  2016-01-08       Impact factor: 4.239

Review 7.  Fine-needle aspiration and core biopsy in the diagnosis of breast lesions: A comparison and review of the literature.

Authors:  Suvradeep Mitra; Pranab Dey
Journal:  Cytojournal       Date:  2016-08-31       Impact factor: 2.091

8.  Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study.

Authors:  Akira Matsui; Yuya Murata; Norikazu Masuda; Kiyoshi Mori; Masato Takahashi; Katsushige Yamashiro; Kenjirou Aogi; Shigeto Maeda; Masahiro Itou; Shinji Ozaki; Kazuya Kuraoka; Yasuyuki Satou; Shu Ichihara; Eriko Tokunaga; Kenichi Taguchi; Takanori Watanabe; Hiroyoshi Suzuki; Aiko Nagayama; Rieko Nishimura
Journal:  Oncotarget       Date:  2019-10-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.